tbResList Print — MCT MCT oil

Filters: qv=333, qv2=%, rfv=%

Product

MCT MCT oil
Description: <p><b>MCT oil</b> — Medium-chain triglyceride oil is a dietary lipid composed of triglycerides esterified predominantly with caprylic acid (C8:0) and capric/decanoic acid (C10:0), although broader definitions of MCTs include C6–C12 fatty acids. It is classified as a nutritional lipid, ketogenic substrate, food ingredient, and pharmaceutical/nutritional excipient. Standard abbreviations are MCT and MCT oil. Commercial MCT oil is usually produced by fractionation and re-esterification of fatty acids derived from coconut or palm-kernel oil and differs substantially from coconut oil because purified MCT oil is generally enriched in C8/C10 rather than lauric acid. C8 is particularly ketogenic, while C10 also has direct metabolic and signaling activities that may not depend entirely on ketone production.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Rapid intestinal hydrolysis and portal absorption of C8/C10 followed by hepatic β-oxidation and ↑ ketone-body production, especially β-hydroxybutyrate and acetoacetate.</li>
<li>Alternative metabolic substrate provision to brain and other tissues through medium-chain fatty acids and ketone bodies, partially bypassing dependence on glucose metabolism.</li>
<li>Mitochondrial fatty-acid oxidation and acetyl-CoA production with altered cellular energy metabolism.</li>
<li>Decanoic acid-specific metabolic and signaling effects, including modulation of mitochondrial metabolism and, in experimental cancer models, inhibition of HGF/c-Met signaling.</li>
<li>Metabolic effects associated with ketogenic dietary strategies, including lower glucose availability and altered insulin signaling when MCT replaces carbohydrate rather than simply adding calories.</li>
<li>Modulation of drug and nutrient delivery through use of MCT as a lipid vehicle or excipient; intestinal permeability and solubilization effects are formulation-dependent.</li>
<li>Redox, inflammatory, and transcriptional changes secondary to altered fatty-acid/ketone metabolism; these effects are context-dependent and should not be treated as consistent direct MCT actions.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> MCTs are hydrolyzed more rapidly than long-chain triglycerides. C8 and C10-derived fatty acids are preferentially transported through the portal circulation to the liver rather than requiring extensive chylomicron-mediated lymphatic transport. They undergo rapid mitochondrial oxidation and can raise circulating ketones within approximately 1–3 hours. C8 generally produces stronger acute ketonemia than C10. Increasing chain length toward C12 increases resemblance to long-chain lipid handling. Oral dose is constrained mainly by gastrointestinal tolerance; diarrhea, abdominal discomfort, cramping, and nausea become increasingly important at higher intakes.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Direct cellular effects of free caprylic or decanoic acid at high micromolar-to-millimolar concentrations should not automatically be attributed to ordinary oral MCT-oil supplementation. Physiologically, the best-supported systemic consequence of oral C8/C10 MCT is rapid substrate delivery and ketogenesis rather than sustained high circulating free-MCFA concentrations. Component-specific cancer findings, especially those reported for isolated decanoic acid, should therefore be identified as C10 findings rather than generalized to all MCT formulations.</p>

<p><b>Clinical evidence status:</b> Established nutritional use and substantial human experience exist for ketogenic nutrition, malabsorption-related nutritional applications, and specialized medical foods. Neurologic evidence includes small randomized trials and meta-analyses showing increased ketone availability and possible cognitive benefits in mild cognitive impairment or Alzheimer's disease, with considerable heterogeneity and possible APOE-dependent response. Cancer evidence remains preclinical to small exploratory human studies, principally as part of ketogenic dietary interventions rather than MCT oil monotherapy. MCT oil is not an established anticancer treatment.</p>

Here are some examples and sources of MCT oils:<br>

• Purified MCT Oil Products:<br>

– Commercial MCT oils (e.g., Nature’s Way MCT Oil, Now Sports MCT Oil) are available as dietary supplements and are often used in both nutritional and pharmaceutical applications.<br>

– These products are refined to contain mostly C8 and C10 fatty acids, which are known for their rapid digestion and absorption.<br>

• Coconut Oil (Fractionated):<br>

– Although traditional coconut oil contains a mix of medium-chain (and longer-chain) fatty acids, fractionated coconut oil has been processed to separate the medium-chain triglycerides (mainly C8 and C10).<br>

– This fractionated form is liquid at room temperature and can serve a similar purpose as purified MCT oil in formulations.<br>

- MCT oil is rapidly metabolized in the liver to produce ketone bodies, making it a common component of ketogenic diets.<br>

<br>
<h3>MCT Oil Mechanistic Effects in Cancer</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Hepatic ketogenesis and ketone availability</td>
<td>↔ / altered substrate availability (context-dependent)</td>
<td>↑ ketone availability</td>
<td>R</td>
<td>Systemic metabolic substrate shift</td>
<td>The dominant reproducible consequence of oral C8/C10 MCT. Antitumor consequences depend strongly on tumor glucose dependence and capacity to utilize ketones.</td>
</tr>

<tr>
<td>2</td>
<td>Glucose and glycolytic dependence</td>
<td>↓ glucose availability advantage (context-dependent)</td>
<td>↔ / ↓ glucose reliance (context-dependent)</td>
<td>R/G</td>
<td>Metabolic pressure on glucose-dependent tumors</td>
<td>Mainly relevant when MCT forms part of a carbohydrate-restricted ketogenic diet. Adding MCT to an otherwise unchanged diet does not necessarily reproduce this effect.</td>
</tr>

<tr>
<td>3</td>
<td>HGF c-Met signaling</td>
<td>↓ c-Met activation and downstream signaling (model-dependent)</td>
<td>Not established</td>
<td>R/G</td>
<td>Growth and metastatic signaling inhibition</td>
<td>Demonstrated primarily with isolated decanoic acid in hepatocellular carcinoma models. This should be recorded as a C10 component-specific mechanism rather than a universal MCT-oil effect.</td>
</tr>

<tr>
<td>4</td>
<td>Mitochondrial and intermediary metabolism</td>
<td>↔ / altered metabolic flux (model-dependent)</td>
<td>↑ fatty-acid oxidation and energy substrate availability</td>
<td>R/G</td>
<td>Metabolic reprogramming</td>
<td>Recent glioblastoma work indicates that medium-chain fats can alter metabolic pathways including pantothenate-associated metabolism, but therapeutic significance remains preclinical.</td>
</tr>

<tr>
<td>5</td>
<td>Insulin and growth-factor signaling</td>
<td>↓ proliferative signaling (context-dependent)</td>
<td>↓ insulin exposure (context-dependent)</td>
<td>R/G</td>
<td>Indirect metabolic modulation</td>
<td>Primarily a consequence of carbohydrate displacement and ketogenic dietary context. It should not be represented as a direct pharmacologic inhibition of insulin or IGF-1 by MCT oil.</td>
</tr>

<tr>
<td>6</td>
<td>Redox and ROS modulation</td>
<td>↔ (context-dependent)</td>
<td>↔ / ↓ oxidative stress (model-dependent)</td>
<td>R/G</td>
<td>Secondary redox modulation</td>
<td>Direction varies with cell type, C8 versus C10 exposure, mitochondrial state, and whether free fatty acids or whole MCT are studied. Evidence does not support assigning a uniform ROS direction to MCT oil.</td>
</tr>

<tr>
<td>7</td>
<td>Drug and nutrient bioavailability</td>
<td>↔</td>
<td>↑ absorption (formulation-dependent)</td>
<td>P/R</td>
<td>Lipid vehicle and absorption enhancement</td>
<td>MCTs are widely used as pharmaceutical and nutraceutical excipients. Digestion products can transiently alter intestinal permeability and MCT can improve solubilization of lipophilic compounds.</td>
</tr>

<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td colspan="2">Dose-limiting gastrointestinal intolerance; strong dependence on C8/C10 composition, dietary carbohydrate intake, achieved ketosis, tumor metabolic phenotype, and adherence.</td>
<td>R/G</td>
<td>Limits predictable anticancer efficacy</td>
<td>Current human oncology evidence largely evaluates ketogenic dietary regimens containing MCT rather than isolated MCT oil. Antitumor efficacy has not been established.</td>
</tr>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp;&nbsp;R: 30 min–3 hr&nbsp;&nbsp;&nbsp;&nbsp;G: &gt;3 hr</p>


<br><br>
<hr>
<br><br>


<p><b>MCT oil and Alzheimer's disease:</b> Alzheimer's disease is associated with reduced cerebral glucose utilization while brain ketone uptake remains relatively preserved. Oral C8/C10 MCT raises circulating ketones that can cross the blood-brain barrier and provide an alternative oxidative fuel. Small randomized controlled trials and meta-analyses report possible improvements in global cognition, particularly among APOE ε4-negative individuals, although results are heterogeneous and the evidence is not sufficient to consider MCT a disease-modifying Alzheimer's therapy.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↑ circulating ketone bodies and delivery of an alternative cerebral energy substrate.</li>
<li>↑ cerebral ketone oxidation despite impaired cerebral glucose metabolism.</li>
<li>Altered mitochondrial energy metabolism and ATP availability.</li>
<li>Decanoic acid-specific neuronal and metabolic effects that may extend beyond ketogenesis.</li>
<li>Secondary modulation of oxidative stress, inflammation, and neuronal signaling (context-dependent).</li>
</ol>

<p><b>Clinical evidence status:</b> Small human randomized trials plus systematic reviews/meta-analyses support a biologically credible cognitive effect but show considerable heterogeneity. Benefits appear stronger in some APOE ε4-negative populations. Evidence supports classification as an investigational nutritional adjunct rather than established Alzheimer's treatment.</p>


<h3>MCT Oil in Alzheimer's Disease</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Ketone bodies</td>
<td>↑</td>
<td>Alternative cerebral fuel</td>
<td>C8/C10 supplementation increases β-hydroxybutyrate and acetoacetate, partially bypassing impaired cerebral glucose utilization.</td>
</tr>

<tr>
<td>2</td>
<td>Brain energy metabolism</td>
<td>↑</td>
<td>Improved substrate availability</td>
<td>Brain ketone uptake remains substantially functional in AD and can provide oxidative energy when glucose utilization is impaired.</td>
</tr>

<tr>
<td>3</td>
<td>Cognition</td>
<td>↑ (context-dependent)</td>
<td>Possible improvement in global cognitive performance</td>
<td>Small controlled trials and meta-analysis indicate benefit, but effect size and responder populations remain uncertain.</td>
</tr>

<tr>
<td>4</td>
<td>APOE genotype response</td>
<td>↑ benefit in APOE ε4-negative subjects (context-dependent)</td>
<td>Response stratification</td>
<td>Several studies report greater cognitive response in APOE ε4-negative participants than APOE ε4 carriers.</td>
</tr>

<tr>
<td>5</td>
<td>Mitochondrial bioenergetics</td>
<td>↑</td>
<td>Alternative acetyl-CoA and ATP production</td>
<td>Medium-chain fatty acids are rapidly oxidized and ketones provide additional mitochondrial substrate.</td>
</tr>

<tr>
<td>6</td>
<td>Oxidative stress</td>
<td>↔ / ↓ (model-dependent)</td>
<td>Secondary neuroprotection</td>
<td>Decanoic acid and ketogenic metabolism can modify cellular redox state, but a consistent direct antioxidant effect of oral MCT oil should not be assumed.</td>
</tr>

<tr>
<td>7</td>
<td>Amyloid beta</td>
<td>? / ↓ (preclinical)</td>
<td>Possible secondary disease-pathway modulation</td>
<td>Evidence is substantially weaker than for cerebral energy rescue. MCT should not currently be characterized primarily as an anti-amyloid treatment.</td>
</tr>

<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>GI tolerance and heterogeneous response</td>
<td>Limits achievable dose and adherence</td>
<td>Diarrhea, abdominal discomfort, nausea, formulation differences, APOE genotype, and achieved ketone concentrations contribute to clinical variability.</td>
</tr>
</table>

Pathway results for Effect on Cancer / Diseased Cells

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,   FAM↝, 1,   glucose↓, 1,  

Cell Death(tgid=5) ⓘ

Ferroptosis↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HGF/c-Met↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumMeta↓, 1,  

Barriers & Transport(tgid=15) ⓘ

CD36/FAT↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioEnh↑, 1,   Dose↝, 1,   eff↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

H2O2↓, 1,   ROS↓, 2,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↓, 1,   ATP↑, 1,   KeyT↑, 6,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 2,   p‑mTOR↑, 1,   mTOR↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Migration(tgid=13) ⓘ

SMAD3↓, 1,   TGF-β↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioEnh↑, 1,   Dose↝, 1,   eff↝, 1,   eff↑, 3,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

KeyT↑, 6,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 11,   memory↑, 2,   neuroP↑, 1,   Obesity↓, 2,   toxicity↓, 2,  
Total Targets: 29

Research papers

Year Title Authors PMID Link Flag
2022In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil TypeYanping Lin36580279https://pubmed.ncbi.nlm.nih.gov/36580279/0
2026Metabolic targeting of pantothenate by medium chain fats in glioblastoma cellsErwann PainPMC13181877https://pmc.ncbi.nlm.nih.gov/articles/PMC13181877/0
2026Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise ReviewChristina HeidtPMC13075030https://pmc.ncbi.nlm.nih.gov/articles/PMC13075030/0
2025Medium-Chain Fatty Acids Selectively Sensitize Cancer Cells to Ferroptosis by Inducing CD36 and ACSL4Kai HanPMC11901882https://pmc.ncbi.nlm.nih.gov/articles/PMC11901882/0
2023The Effects of Medium Chain Triglyceride for Alzheimer's Disease Related Cognitive Impairment: A Systematic Review and Meta-AnalysisLina SunPMC10357178https://pmc.ncbi.nlm.nih.gov/articles/PMC10357178/0
2023Decanoic Acid Exerts Its Anti-Tumor Effects via Targeting c-Met Signaling Cascades in Hepatocellular Carcinoma ModelMin Hee YangPMC10571573https://pmc.ncbi.nlm.nih.gov/articles/PMC10571573/0
2022Potential of Capric Acid in Neurological Disorders: An OverviewNikhila Shekhar36342577https://pubmed.ncbi.nlm.nih.gov/36342577/0
2022The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic ReviewTomas J Chapman-LopezPMC9579472https://pmc.ncbi.nlm.nih.gov/articles/PMC9579472/0
2021Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studiesKonstantinos I AvgerinosPMC7050425https://pmc.ncbi.nlm.nih.gov/articles/PMC7050425/0
2021The medium-chain fatty acid decanoic acid reduces oxidative stress levels in neuroblastoma cellsJanine MettPMC7971073https://pmc.ncbi.nlm.nih.gov/articles/PMC7971073/0
2020Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer's diseasePratishtha Chatterjee31953123https://pubmed.ncbi.nlm.nih.gov/31953123/0
2018Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot StudyJosé Enrique de la Rubia Ortí30056419https://pubmed.ncbi.nlm.nih.gov/30056419/0
2018Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolismYing WangPMC5805166https://pmc.ncbi.nlm.nih.gov/articles/PMC5805166/0
2017Coconut (Cocos nucifera) Ethanolic Leaf Extract Reduces Amyloid-β (1-42) Aggregation and Paralysis Prevalence in Transgenic Caenorhabditis elegans Independently of Free Radical Scavenging and Acetylcholinesterase InhibitionRafael Vincent ManaloPMC5489803https://pmc.ncbi.nlm.nih.gov/articles/PMC5489803/0
2017How does coconut oil affect cognitive performance in alzheimer patients?José Enrique De la Rubia Ortí28421789https://pubmed.ncbi.nlm.nih.gov/28421789/0
2015COCONUT OIL: NON-ALTERNATIVE DRUG TREATMENT AGAINST ALZHEIMER´S DISEASEIván Hu Yang26667739https://pubmed.ncbi.nlm.nih.gov/26667739/0
2014Effects of Caprylic Triglyceride on Cognitive Performance and Cerebral Glucose Metabolism in Mild Alzheimer’s Disease: A Single-Case ObservationBrian Andrew FarahPMC4099555https://pmc.ncbi.nlm.nih.gov/articles/PMC4099555/0
2013Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer’s diseaseSteven Douglas MaynardPMC3810342https://pmc.ncbi.nlm.nih.gov/articles/PMC3810342/0
2013Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s diseaseSteven Douglas MaynardPMC3810439https://pmc.ncbi.nlm.nih.gov/articles/PMC3810439/0